Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20838548 | 0.98 | MEN1 (0.63) | MEN1KMT2ACYP2D6TNKSTNKS2 | |
| SCHEMBL5735015 | 0.84 | MEN1 (0.56) | MEN1KMT2ACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL20883790 | 0.83 | MEN1 (0.66) | MEN1KMT2ACYP2D6HRH3MGLL | |
| SCHEMBL6622933 | 0.80 | MEN1 (0.62) | MEN1KMT2ACYP2D6MGLLALDH1A1 | |
| SCHEMBL9254331 | 0.80 | MEN1 (0.66) | MEN1KMT2ACYP2D6HRH3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27829790 | 0.78 | MEN1 (0.64) | MEN1KMT2ACYP2D6HRH3MGLL | |
| Hydrochloric Acid SCHEMBL9252134 | 0.78 | MEN1 (0.69) | MEN1KMT2ACYP2D6HRH3ALDH1A1 | |
| SCHEMBL1582773 | 0.77 | KMT2A (0.96) | MEN1KMT2ACYP2D6MGLLALDH1A1 | |
| Hydrochloric Acid SCHEMBL7037848 | 0.77 | MEN1 (0.39) | MEN1KMT2ACYP2D6TNKSTNKS2 | |
| SCHEMBL28750644 | 0.77 | MEN1 (0.58) | MEN1KMT2ACYP2D6HRH3MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | MERCK PATENT GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| EP-3371166-B1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| EP-3371166-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | Merck Patent GmbH (DE) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017076484-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017076484-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | WO | disclosed |
| EP-1060162-B1 | URETHANES DERIVED FROM AZACYCLOALKANES, THIO AND DITHIO ANALOGUES, PRODUCTION AND USE THEREOF AS 2,3 EPOXYSQUALENE LANESTEROL CYCLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-03-19 | — | — | EP | disclosed |
| US-6339096-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERLIPIDAEMIAS, HYPERCHOLESTEROLAEMIAS AND ATHEROSCLEROSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-01-15 | — | — | US | disclosed |
| CN-1281434-A | Urethanes derived from azacycloalkanes, thio and dithio analogues, production and use thereof as 2,3 epoxysqualene lanesterol cyclase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | TNKS, TANK, TBKBP1 | MEN1 3993/4885KMT2A 530/4885CYP2D6 2103/4885 |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | TNKS, TANK, TBKBP1 | MEN1 3993/4885KMT2A 530/4885CYP2D6 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.